WALTHAM, Mass. — Vizgen, Inc. said it will debut a broad technology roadmap later this month detailing new spatial multi-omics capabilities aimed at accelerating drug discovery, advancing disease research, and enabling new applications such as organoid analysis.
The company plans to present the roadmap at the Advances in Genome Biology and Technology (AGBT) General Meeting, scheduled for February 23–26 in Orlando, Florida. The presentation will outline developments across Vizgen’s platform portfolio, including expanded applications of its MERSCOPE Ultra system and progress toward several next-generation capabilities.
A key focus will be Vizgen’s work in spatially resolved molecular profiling of organoids, driven by collaborations with the research community. The company said its latest efforts build on peer-reviewed studies showing the value of spatial transcriptomics for characterizing non-animal models. This approach aligns with a broader industry shift toward New Approach Methodologies, as well as increased use of lab-grown tissues encouraged by U.S. regulatory and research agencies.
“At Vizgen, we are working to develop new capabilities for researchers who are currently working with or want to work with organoids, especially for earlier, more predictive drug evaluation,” said Jiang He, VP & Portfolio Owner, Reagents & Sci. Affairs, at Vizgen. “As the industry shifts toward more human-relevant and translational model systems, we’re preparing for the era to come through collaborative R&D work with the global scientific community and partners.”
Looking ahead to 2026, Vizgen said it plans to enhance the MERSCOPE Ultra platform by expanding its portfolio of predesigned panels and introducing a modular customization feature that allows researchers to add gene targets without redesigning experiments. The company said the updates are intended to support faster, hypothesis-driven discovery.
The roadmap presentation will also cover workflow innovations, including new approaches to upstream sample preparation and downstream bioinformatics. Vizgen said it is releasing updated MERSCOPE slides with optimized chemistry, to be followed by a streamlined pre-analytical workflow designed to support protein co-detection with greater flexibility and performance.
In addition, the company plans to preview scalable image analysis technologies under development, including a cloud-based platform for next-generation MERFISH data and advanced segmentation algorithms. Executives and research leaders will also share progress toward longer-term initiatives such as thick-tissue, or three-dimensional, spatial imaging and analysis.
“Vizgen is advancing a bold roadmap to unlock deeper biological insight through spatial multi-omics,” said Rob Carson, CEO of Vizgen. “We’re excited to be expanding Vizgen’s validated applications for organoid analysis, particularly given regulatory body and research community interest in alternative models. Our pipeline is consistent with our purpose: a map for every disease, a path for every cure.”
